Pitney Pharmaceuticals Pty Limited

Newsouth Innovations Pty Limited

Roger Aston

David Lawson Morris

Koji Tanaka

Nobuharu Andoh

Tomokazu Hino

Osamu Sanpei

Mohammad Hossein Pourgholami

Tetsuo Toga

Javed Akhter

Krishna Pillai

Richard Mollard

The present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of cancer and mTOR (mammalian Target of Rapamycin) pathway related diseases. In particular it relates to the use of AADs administered at particular dose amounts in order to achieve therapeutic effects.

Use of aminoacetonitrile compounds for the treatment of infection and disease

The present invention relates to compositions containing one or more of the compounds contained in bromelain, or salts, solvates or prodrugs thereof, and one or more mucolytic agents, or salts, solvates or prodrugs thereof, for treatment of diseases involving mucin, especially mucin secreting cancers, or diseases involving blood clots (thrombi).

Treatment of diseases involving mucin

The present invention relates to synergistic compositions comprising bromelain, or a proteolytic fraction thereof, and cysteamine or a metabolite, pharmaceutically acceptable salt, solvate or prodrug thereof The invention also relates to methods and uses of such compositions for the treatment of diseases involving mucin.

Compositions and methods for the treatment of diseases involving mucin

The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein Ris a hydrogen atom, an alkyl group and the like, R, R, and Rare the same or different and each is a hydrogen atom, an alkyl group and the like, Rand Rare the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Aris a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, or &#x2014;N(R)&#x2014; wherein Ris a hydrogen atom, a (C-C)alkyl group and the like, or a pharmacologically acceptable salt thereof. 

Anti-cancer agent comprising aminoacetonitrile compound as active ingredient

The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein Ris a hydrogen atom, an alkyl group and the like, R, R, and Rare the same or different and each is a hydrogen atom, an alkyl group and the like, Rand Rare the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Aris a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, or &#x2014;N(R)&#x2014; wherein Ris a hydrogen atom, a (C-C) alkyl group and the like, or a pharmacologically acceptable salt thereof.

Anticancer agent comprising aminoacetonitrile compound as active ingredient

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoacetonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Compounds for the treatment of mTOR pathway related diseases

The present invention relates to an anticancer agent having a high safety and a superior anticancer activity, and an anticancer agent containing, as an active ingredient, an aminoacetonitrile compound represented by the formula (I) wherein Ris a hydrogen atom, an alkyl group and the like, R, R, and Rare the same or different and each is a hydrogen atom, an alkyl group and the like, Rand Rare the same or different and each is a hydrogen atom, a halogen atom and the like, m is 0 or 1, R is a halogen atom, a cyano group, a nitro group, a phenyl group optionally substituted by an alkyl group and the like, an alkyl group and the like, Aris a phenyl group, a naphthyl group, a pyridyl group, a pyrazolyl group, or the like, each of which is optionally substituted by a halogen atom, a cyano group, a nitro group, alkyl group and the like, and W is &#x2014;O&#x2014;, &#x2014;S&#x2014;, &#x2014;SO&#x2014;, or &#x2014;N(R)&#x2014; wherein Ris a hydrogen atom, a (C-C)alkyl group and the like, or a pharmacologically acceptable salt thereof. 

The present invention relates to pharmaceutical combinations comprising aminoacetonitrile derivatives and anticancer compounds. Further, the present invention relates to these pharmaceutical combinations for use in the treatment of cancer.

Pharmaceutical combinations for the treatment of cancer

The present invention relates to compounds for the treatment of mTOR (mammalian Target Of Rapamycin) pathway related diseases. Specifically, the present invention relates to the use of aminoactonitrile derivatives (AADs) in the treatment of mTOR pathway related diseases.

Growing community of inventors

Manly, Australia

Roger Aston